FERRARO, Diana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.259
AS - Asia 5.241
EU - Europa 4.922
SA - Sud America 981
AF - Africa 144
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 3
Totale 25.600
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.051
GB - Regno Unito 1.728
SG - Singapore 1.613
CN - Cina 1.237
VN - Vietnam 774
BR - Brasile 731
HK - Hong Kong 727
IT - Italia 665
DE - Germania 479
SE - Svezia 410
FI - Finlandia 389
RU - Federazione Russa 242
FR - Francia 240
UA - Ucraina 200
TR - Turchia 133
BG - Bulgaria 129
IN - India 115
KR - Corea 112
CA - Canada 94
ID - Indonesia 94
AR - Argentina 93
MX - Messico 73
BD - Bangladesh 69
ES - Italia 64
NL - Olanda 55
CZ - Repubblica Ceca 51
AU - Australia 49
IQ - Iraq 49
PL - Polonia 49
JP - Giappone 48
AT - Austria 43
ZA - Sudafrica 42
EC - Ecuador 39
AE - Emirati Arabi Uniti 34
IE - Irlanda 34
CL - Cile 30
PK - Pakistan 29
IR - Iran 27
MY - Malesia 26
BE - Belgio 25
CH - Svizzera 24
CO - Colombia 22
VE - Venezuela 22
MA - Marocco 20
PH - Filippine 20
EG - Egitto 19
PY - Paraguay 17
KE - Kenya 16
LT - Lituania 16
TN - Tunisia 16
JO - Giordania 14
DK - Danimarca 12
TW - Taiwan 12
PE - Perù 11
SA - Arabia Saudita 11
UY - Uruguay 11
BZ - Belize 10
GE - Georgia 10
UZ - Uzbekistan 10
AZ - Azerbaigian 8
NP - Nepal 8
PT - Portogallo 8
DO - Repubblica Dominicana 7
IL - Israele 7
DZ - Algeria 6
GR - Grecia 6
OM - Oman 6
QA - Qatar 6
RO - Romania 6
AL - Albania 5
HU - Ungheria 5
KZ - Kazakistan 5
LB - Libano 5
NO - Norvegia 5
RS - Serbia 5
SI - Slovenia 5
TH - Thailandia 5
BB - Barbados 4
BO - Bolivia 4
JM - Giamaica 4
PA - Panama 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
ET - Etiopia 3
GA - Gabon 3
HN - Honduras 3
HR - Croazia 3
KW - Kuwait 3
LK - Sri Lanka 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BN - Brunei Darussalam 2
EE - Estonia 2
EU - Europa 2
GT - Guatemala 2
Totale 25.563
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Ashburn 1.384
Santa Clara 1.330
Southend 1.203
Singapore 951
Woodbridge 872
Hong Kong 715
Seattle 711
Houston 698
Chandler 624
Cambridge 605
Wilmington 551
San Jose 368
Ann Arbor 354
Helsinki 326
Dearborn 317
London 300
Chicago 292
Jacksonville 291
Nyköping 284
Ho Chi Minh City 252
Beijing 219
Los Angeles 207
Hanoi 183
Modena 175
Hefei 165
New York 165
Council Bluffs 150
The Dalles 149
San Diego 143
Munich 135
Sofia 122
Princeton 120
Salt Lake City 109
Moscow 86
Shanghai 86
Seoul 81
Lauterbourg 78
Eugene 73
Jakarta 66
São Paulo 62
Dallas 61
Buffalo 57
Frankfurt am Main 54
Tampa 51
Elk Grove Village 50
Bremen 47
Orem 45
Izmir 44
Redwood City 42
Milan 40
Norwalk 39
Da Nang 38
Phoenix 37
Warsaw 35
Columbus 34
Boardman 33
Rio de Janeiro 32
Málaga 30
Redondo Beach 30
Brno 29
Manchester 29
Tokyo 29
Dublin 28
Guangzhou 28
Rome 28
Sterling 28
Turku 28
Miami 27
Vienna 27
Haiphong 26
Toronto 26
Amsterdam 25
Fremont 25
Lancaster 24
Melbourne 24
Chennai 23
Seongnam 23
Stockholm 23
Dulles 22
Hillsboro 22
Johannesburg 22
Kunming 22
Baghdad 21
Boston 20
Nuremberg 20
Atlanta 19
Buenos Aires 18
Edinburgh 18
Falls Church 18
Brooklyn 17
Brussels 17
Mexico City 17
Paris 17
Piacenza 16
Brasília 15
Chevy Chase 15
Kilburn 15
Prescot 15
San Francisco 15
Totale 18.501
Salva come PNG Salva come JPEG
Nome #
Definitive childlessness in women with multiple sclerosis: a multicenter study 668
Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. 443
Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis 439
Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis 389
Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV 388
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient 386
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study 371
A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord 369
iNKT cells in secondary progressive multiple sclerosis patients display pro-inflammatory profiles 365
False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. 360
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 353
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence 353
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: Results from an observational study 350
Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis 347
Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study 343
Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study 333
Paroxysmal ventricular tachicardia and pure right insular stroke 333
Acute hemichorea as unusual first multiple sclerosis presentation 326
Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome 323
Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients 316
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study 302
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 301
Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia 300
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 296
Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis 287
Inter-center agreement in the interpretation of oligoclonal bands 286
Methylprednisolone-induced toxic hepatitis after intravenous pulsed therapy for multiple sclerosis relapses 283
Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study 280
Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band‐negative patients with suspected multiple sclerosis 280
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM 277
Semiautomated segmentation of the human spine based on echoplanar images 277
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis 273
Antiepileptic drugs in the treatment of headache: Neuroprotective effect or something else? 269
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 267
Acute necrotizing encephalopathy: A relapsing case in a European adult [4] 259
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? 259
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS 255
Severe anemia in a patient with multiple sclerosis treated with natalizumab 253
Diagnostics of dysimmune peripheral neuropathies 252
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 251
Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine 246
Diagnostics of anti-MAG antibody polyneuropathy 246
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis 245
Abnormal Circadian Modification of Aδ-Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome 245
Systematic assessment and characterization of chronic pain in multiple sclerosis patients 243
Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients 242
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? 240
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 238
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 233
Charcot-Marie-Tooth and pain: Correlations with neurophysiological, clinical, and disability findings 232
Antiepileptic drugs in the preventive treatment of migraine in children and adolescents 230
The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate 229
Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study 226
Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study 225
Habituation to Pain in "Medication Overuse Headache": A CO2 Laser-Evoked Potential Study 224
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis 224
Detection of Neurofilament Light Chain with Label-Free Electrolyte-Gated Organic Field-Effect Transistors 213
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study) 212
Topiramate in the prevention of pediatric migraine: Literature review 212
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: Acetylcholinesterase activity cannot be considered a useful biomarker 210
Left thalamomegaly in a patient with partial epilepsy 210
Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement 209
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study 208
The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study 208
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 207
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients 201
Evidence of different spinal pathways for the warmth evoked potentials 200
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis 200
Multiple attack study on the available triptans in Italy versus placebo 196
Acute hemichorea as unusual first multiple sclerosis presentation: two case reports 195
Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders 194
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 191
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 190
Antiepileptic drugs in migraine prophylaxis: state of the art 189
Treatment response score to glatiramer acetate or interferon beta-1a 185
A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis 183
Occupational head injury and subsequent glioma 181
Informing MS patients on treatment options: a consensus on the process of consent taking 179
Risk of secondary progressive multiple sclerosis: A longitudinal study 174
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis 169
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients 169
Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis 168
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 168
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 163
Cell-based assays for the detection of MOG antibodies: a comparative study 162
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 162
A novel SOD1 mutation in a young ALS patient associated with slowly progressive clinical course 155
Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus 153
Microglia activation: A role for mitochondrial DNA? 151
Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis 150
Modulation of tregs and inkt by fingolimod in multiple sclerosis patients 145
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder 134
A study of the CD45 exon 4 C77G polymorphism in a patient affected both by multiple sclerosis and pulmonary Langerhans' cell histiocytosis 132
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 129
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years 128
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 125
Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer 123
Exploring the Role of Diabetes in ALS: A Population-Based Cohort Study 120
Early clinical markers of aggressive multiple sclerosis 119
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score 116
Totale 24.418
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.185
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.185
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021364 0 0 0 0 0 0 0 0 0 0 224 140
2021/20222.370 216 274 249 93 40 134 107 141 252 225 403 236
2022/20231.749 198 206 146 181 198 250 21 191 193 13 102 50
2023/20241.247 33 77 60 158 229 108 147 155 30 15 63 172
2024/20254.290 151 37 47 322 911 713 198 213 499 242 382 575
2025/20267.847 525 336 704 1.013 1.399 673 967 476 842 727 185 0
Totale 25.807